ArticleChemical biology & drug design2011
High-throughput analysis of an RNAi library identifies novel kinase targets in Trypanosoma brucei.
Article in Chemical biology & drug design, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 35 citations in OpenAlex.
- Molecular docking to homology models of human and Trypanosoma brucei ERK8 that identified ortholog-specific inhibitors.PLoS neglected tropical diseases · 2025Article
- Structure, function and druggability of the African trypanosome flagellum.Journal of cellular physiology · 2022Review
- Identification of inhibitors of an unconventional Trypanosoma brucei kinetochore kinase.PloS one · 2019Article
- High Throughput and Computational Repurposing for Neglected Diseases.Pharmaceutical research · 2018Review
- Dictyostelium Erk2 is an atypical MAPK required for chemotaxis.Cellular signalling · 2018Article
- RNAi screening identifies Trypanosoma brucei stress response protein kinases required for survival in the mouse.Scientific reports · 2017Article
- ERKing Trypanosoma: PCNA phosphorylation as novel target.Cell cycle (Georgetown, Tex.) · 2016Article
- Extracellular-signal regulated kinase 8 of Trypanosoma brucei uniquely phosphorylates its proliferating cell nuclear antigen homolog and reveals exploitable properties.Cell cycle (Georgetown, Tex.) · 2016Article
- Glycogen Synthase Kinase 3β Promotes the Endocytosis of Transferrin in the African Trypanosome.ACS infectious diseases · 2016Article
- Cyclin-Dependent Kinase CRK9, Required for Spliced Leader trans Splicing of Pre-mRNA in Trypanosomes, Functions in a Complex with a New L-Type Cyclin and a Kinetoplastid-Specific Protein.PLoS pathogens · 2016Article
- Ribose 5-phosphate isomerase B knockdown compromises Trypanosoma brucei bloodstream form infectivity.PLoS neglected tropical diseases · 2015Article
- Kinases as druggable targets in trypanosomatid protozoan parasites.Chemical reviews · 2014Review
- Regulators of Trypanosoma brucei cell cycle progression and differentiation identified using a kinome-wide RNAi screen.PLoS pathogens · 2014Article
- Antiparasitic chemotherapy: from genomes to mechanisms.Annual review of pharmacology and toxicology · 2014Review
- Luminescent multiplex viability assay for Trypanosoma brucei gambiense.Parasites & vectors · 2013Article
- Hypothemycin, a fungal natural product, identifies therapeutic targets in Trypanosoma brucei [corrected].eLife · 2013Article
- Identification of essential and non-essential protein kinases by a fusion PCR method for efficient production of transgenic Trypanosoma brucei.Molecular and biochemical parasitology · 2013Article
- Global quantitative SILAC phosphoproteomics reveals differential phosphorylation is widespread between the procyclic and bloodstream form lifecycle stages of Trypanosoma brucei.Journal of proteome research · 2013Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
New drugs are needed to treat human African trypanosomiasis because the currently approved treatments are toxic or limited in efficacy. One strategy for developing new drugs involves discovering novel genes whose products can be targeted for modulation by small-molecule chemotherapeutic agents. The Trypanosoma brucei genome contains many genes with the potential to become such targets. Kinases represent one group of genes that regulate many important cell functions and can be modulated by small molecules, thus representing a promising group of enzymes to screen for potential therapeutic targets. RNAi screens could help identify the most promising kinase targets, but the lack of suitable assays represents a barrier for optimizing the use of this technology in T. brucei. Here, we describe an RNAi screen of a small RNAi library targeting 30 members of the T. brucei kinome utilizing a luciferase-based assay. This screen both validated the luciferase-based assay as a suitable method for conducting RNAi screens in T. brucei and also identified two kinases (CRK12 and ERK8) that are essential for normal proliferation by the parasite.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.